Details for Patent: 10,940,156

Which drugs does patent 10,940,156 protect, and when does it expire?

Patent 10,940,156 protects ZULRESSO and is included in one NDA.

This patent has thirty-nine patent family members in twenty countries.

Summary for Patent: 10,940,156

Title:	Neuroactive steroids, compositions, and uses thereof
Abstract:	Described herein are methods of treating a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).
Inventor(s):	Stephen Jay Kanes, Helen Colquhoun
Assignee:	Sage Therapeutics Inc
Application Number:	US16/718,430
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 10,940,156

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sage Therap Supernus	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		DISCN	Yes	No	10,940,156					METHOD OF TREATING POSTPARTUM DEPRESSION

International Family Members for US Patent 10,940,156

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	107833
Argentina	123571
Australia	2017229656
Australia	2022283769
Brazil	112018067998